DARA BioSciences Inc (NASDAQ:DARA)

0.85
Delayed Data
As of Jul 28
 -0.0075 / -0.87%
Today’s Change
0.67
Today|||52-Week Range
1.43
-3.41%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$16.9M

Company Description

DARA BioSciences, Inc. is a pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. The company's product portfolio includes Soltamox, Gelclair, Bionect and KRN5500. Soltamox offers a choice to patients who prefer or need a liquid form of tamoxifen. Gelclair is an alcohol-free bioadherent oral rinse gel for rapid and effective relief of pain associated with oral mucositis caused by chemotherapy and radiation treatment. The company markets Bionect, a topical treatment for skin irritation and burns associated with radiation therapy, in U.S. oncology/radiology markets. DARA BioSciences was founded by Steven Gorlin on June 22, 2002 and is headquartered in Raleigh, NC.

Contact Information

DARA BioSciences, Inc.
8601 Six Forks Road
Raleigh North Carolina 27615
P:(919) 872-5578
Investor Relations:
(908) 938-1475

Employees

Shareholders

Other institutional7.32%
Mutual fund holders0.66%
Individual stakeholders0.42%

Top Executives

David J. DrutzExecutive Chairman & Chief Medical Officer
Christopher G. ClementPresident, Chief Executive Officer & Director
David L. TousleyChief Financial Officer & Executive Vice President
Mary Kay DelmedicoVice President-Scientific & Regulatory Affairs
John C. PetrolinoChief Compliance Officer & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account